Drug Trial Radar · NCT05824065
Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss
Last checked: Nov 19, 2026Latest source record: Feb 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
504
Planned (sponsor's estimate)
Start
Jan 2025
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- EMSIndustry
- Sponsor type
- Industry
- First posted
- Apr 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.
Conditions
- Female Pattern Baldness
Interventions
OMA102Drug
1 mg
OMA102Drug
2 mg
PlaceboDrug
OMA102 - Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
EMS
Hortolândia, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.